RMP has the advantage of killing low or non-replicating
M. tuberculosis, thus complementing INH activity and allowing
the sterilization of lesions. Unfortunately, it has several limits
because its concentrations in CSF do not exceed 10% of those in
plasma,55 its absorption is negatively influenced by food and
antacids56 and it has a relevant protein binding action that can
significantly reduce its clinical efficacy.57 RMP is officially recommended
at the dose of 10e20 mg/kg/day45,46 but, considering the
MIC of susceptible M. tuberculosis and the concentrations reached
in CSF of children,58 it has been recommended to administer the
highest dosage in young children and infants